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Abstract
The burden of cardiovascular disease (CVD) cannot be fully addressed by therapy targeting known pathophysiological
pathways. Even with stringent control of all risk factors CVD events are only diminished by half. A number of additional
pathways probably play a role in the development of CVD and might serve as novel therapeutic targets. Genome wide
expression studies represent a powerful tool to identify such novel pathways. We compared the expression profiles in
monocytes from twenty two young male patients with premature familial CAD with those from controls matched for age,
sex and smoking status, without a family history of CVD. Since all patients were on statins and aspirin treatment, potentially
affecting the expression of genes in monocytes, twelve controls were subsequently treated with simvastatin and aspirin for 6
and 2 weeks, respectively.
By whole genome expression arrays six genes were identified to have differential expression in the monocytes of patients
versus controls; ABCA1, ABCG1 and RGS1 were downregulated in patients, whereas ADRB2, FOLR3 and GSTM1 were
upregulated. Differential expression of all genes, apart from GSTM1, was confirmed by qPCR. Aspirin and statins altered gene
expression of ABCG1 and ADBR2. All finding were validated in a second group of twenty four patients and controls.
Differential expression of ABCA1, RSG1 and ADBR2 was replicated. In conclusion, we identified these 3 genes to be expressed
differently in CAD cases which might play a role in the pathogenesis of atherosclerotic vascular disease.
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Introduction
Cardiovascular disease (CVD) remains the major worldwide
cause of morbidity and mortality. Atherosclerosis, the major
underlying disease process of CVD, is highly prevalent in western
society and its progression is dependent upon genetic and
environmental risk factors [1]. Despite currently available therapy
targeting known factors, reduction of CVD event rates has never
surpassed 50% [2]. A better understanding of the complex
pathophysiology of CVD is required for the identification of new
therapy targets. Through recent efforts to unravel the molecular
basis of coronary artery disease (CAD) by Genome Wide
Association Studies (GWAS) and follow up of some of these loci,
clues for novel pathways have indeed been discovered, such as the
SORT1 pathway resulting in CAD via lipid metabolism [3].
Another powerful tool for the identification of such novel
pathways in disease is Whole Genome Expression profiling.
Numerous studies have applied gene expression profiling of
carotid, coronary and thoracic arterial wall tissue to identify novel
genes involved in atherogenesis [4]. However, only a few studies
have determined gene expression profiles in circulating cells.
Monocytes are an attractive cell type for this type of approach
since they; play a pivotal role in a number of crucial steps in
atherogenesis, are in contact with the diseased endovascular lumen
and as such may serve as reporter cells, transcribe almost 10,000
genes [5] and are easily accessible both for research and possibly
for future diagnostic applications [6].
We performed a study in which we compared monocyte gene
expression profiles between young CAD patients with a hereditary
background for CVD and controls matched for age, gender and
smoking status without a family history. To control for the
potential effect of aspirin and statin on differential gene expression,
the controls were given these medication to test the effect on the
candidate genes identified from expression profiling.
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Clinical characteristics
Baseline characteristics of the 22 patients and controls are
presented in Table 1. Patients used statin (95%), aspirin (86%),
beta-blockers (73%), ACE-inhibitors (41%) and nitrates (23%).
None of the controls used any medication. In the 12 healthy
subjects given statin and aspirin, LDL-cholesterol levels fell
significantly from 2,960,6 mmol/L to 1,660,6 mmol/L following
the 6 week treatment period (p=0.0002).
In comparison to the study group in the replication group the
mean age of first event of CAD and the mean systolic blood
pressure was higher. The number of cases who suffered from a MI
(54%) and the number of individuals with a history of dyslipidemia
was lower. The medication use in the patients was similar to the
discovery cohort. Details of the replication group can be found in
the supplement (Table S1).
Differential gene expression and correction for
medication use
Six genes were differentially expressed between the monocytes
of patients and controls. The ATP-binding cassette, sub-family A
(ABCA1; p=0.0007), ATP-binding cassette, sub-family G (ABCG1;
p=0.0001) and Regulator of G-protein signalling 1 (RGS1;
p=0.008) were down regulated in the patients. In contrast, the
Adrenergic receptor, beta 2 (ADRB2; p=0.007), Folate receptor 3
(gamma) (FOLR3; p=0.04) and Glutathione S-transferase mu 1
(GSTM1; p=0.01) were up regulated in the patients. Differential
expression was confirmed by qPCR for ABCA1 (Hs02565169_s1);
ABCG1 (Hs00245154_m1); RGS1 (Hs00175260_m1); ADRB2
(Hs00240532_s1);FOLR3 (Hs00357145_g1) and GSTM1
(Hs02341469_m1) by qPCR. No difference in expression of
GSTM1 was found by qPCR. For the other genes, the direction
and magnitude of the relative fold changes of the microarray and
qPCR experiments were comparable as depicted in figure 1
(p.0.05), except for FOLR3 where the magnitude was signifi-
cantly higher in the qPCR experiments (p=0.02). Subsequently,
statin and aspirin were started in control subjects and after 6 weeks
we ascertained the expression of the 6 genes by qPCR. No
significant effect of therapy was observed on the expression of
ABCA1, FOLR3 or RGS1 (Figure 2). However the expression of
both ABCG1 and ADRB2 decreased significantly following
treatment p=0.001 and p=0.04 respectively. Finally in the
replication group we could confirm the differential expression of
ABCA1, ADBR2 and RSG1 (figure 3).
Discussion
The aim of our study was to identify novel players in the
progression of atherosclerosis. Therefore, we studied gene
expression profiles of circulating monocytes of CAD patients and
compared the profiles with matched healthy controls and we
found that ABCA1, ABCG1, RGS1, ADRB2 and FOLR3 were
differentially expressed in patients. To match for medication use
between patients and controls, statins and aspirin were given to the
healthy controls. Differentially expression of two of the five genes
was shown to be affected by medication (ABCG1 and ADBR2).
Finally we replicate three of the 5 genes found in our replication
group.
So far, this is the largest study to determine differential whole
gene expression in circulating monocytes in carefully selected early
onset myocardial infarction patients and healthy controls. In
addition, this is the first study determining the effect of simvastatin
and aspirin on selected gene expression in vivo [7–9].
Previously, Patino and co workers used SAGE to determine
gene expression differences in monocytes between two elderly
patients with carotid atherosclerosis without a positive family
history for CVD and two controls [10]. A total of 297 candidate
genes were shown to be 1.5 fold increased in expression and 267
genes had a 1.5 fold decreased expression. To select candidate
genes for follow up these researchers applied two additional
criteria; low presence in controls and in non-monocytic tissues.
This resulted in six candidate genes all of which were regulatory
genes or transcriptional factors: Finkel-Biskis-Jinkins osteosarcoma
gene (FOS), Dual specificity phosphatise 1 (DUSP1), nuclear factor
of kappa light polypeptide gene enhancer in B cells inhibitor-a
(NFKBIA) inhibitor of DNA binding 2 (ID2), period homolog 1
(PER1) and sin3-associated polypeptide (SAP30). The authors
validated their findings in a second cohort consisting of 25 older
patients with carotid atherosclerosis and 19 controls.
Schirmer and co workers compared monocyte gene expression
differences between 18 CVD patients and 13 controls [11]. The
average age of the event of their partcipants was higher (55.867.9
years) and the patients less frequently has a family history of CVD
(77.8%). As controls, they chose 13 individuals who had
undergone a coronary angiogram because of an intermediate to
high risk of CVD but showed no significant coronary abnormal-
ities, which does not exclude CAD [12]. Schirmer et al [8]
identified 65 differentially expressed genes. Of this list 6 genes
were validated; chemokine (C-C motif) ligand 3 (CCL3), potassium
Table 1. Baseline characteristics Patients and Controls.
Patients Controls
(n=22) (n=22)
Baseline characteristics
Age 6 sd (years) 43,463,8 43,163,3
Age of Myocardial Infarction 6 sd (years) 36,365,7 na
Family History of early-onset CVD (n,%) 22 (100) 0
Hx of Hyperlipidemia (n,%) 6 (27) 0
Hx of Hypertension (n,%) 4 (18) 0
Hx of Diabetes (n,%) 0 0
Hx of Smoking (n,%) 13 (59) 7 (32)
Current Smoking (n,%) 6 (27) 6 (27)
Biometrics
Systolic Bloodpressure 6 sd (mmHg) 130,6619,3 131,6610,1
Diastolic Bloodpressure 6 sd (mmHg) 85,8610,1 84610,1
BMI 6 sd (kg/m2) 27,663,2 25,363,1
Lipid and Glucose values
Total Cholesterol 6 sd (mmol/L) 4,360,7 5,160,9
LDL-cholesterol 6 sd (mmol/L) 2,360,8 3,160,7
HDL-cholesterol 6 sd (mmol/L) 1,260,3 1,360,3
Triglycerides* (mmol/L) 1,3 (0,9–1,6) 1,0 (0,7–1,9)
Apolipoprotein-A 6 sd (g/L) 1,460,2 1,460,2
Apolipoprotein-B 6 sd (g/L) 0,960,2 0,960,2
Glucose 6 sd (mmol/L) 5,360,6 4,960,4
Data are presented as mean 6 standard deviation (sd) or
median (interquartile range)*.
Hx indicates history; LDL indicates low-density lipoprotein and
HDL indicates high-density lipoprotein.
doi:10.1371/journal.pone.0032166.t001
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(ERG1), potassium voltage-gated channel, subfamily H (ecg-
related), member 6 (ERG2), FBJ murine osteosarcoma viral
oncogene homolog (FOS), zinc finger protein 436 (ZNF436) and
zinc finger protein 202 (ZNF202). FOS was the only one of the 6
genes also reported by Patino et al [10].
The two studies conducted so far on monocyte gene expression
in vivo have either studied patients with poorly defined phenotypes
[10], did not match patients and controls with great care [11,13]
and were smaller in size [10,11,14]. Interestingly, except for FOS,
none of the identified genes were consistently differentially
expressed in these two studies. Our in vivo finding that statin and
Figure 1. Differential gene expression in patients versus controls validated by qPCR in the discovery set. The X-axis depicts the relative
fold changes in gene expression in the patients compared to controls. For each gene the first (pale grey) bar depicts the fold change in microarray
expression levels, the second (mid grey) bar shows the change in microarray intensities and the final (black) bar shows the qPCR 2exp DDCT change.
Values are given as mean + SD. A relative fold change of #1o r21 indicates no effect.
doi:10.1371/journal.pone.0032166.g001
Figure 2. Differential gene expression in controls due to medication. The x-axis the average change in expression following the use of
statins and aspirin depicted as 2expDDCT. Values are given as mean + SD. A relative fold change of #1o r21 indicates no effect. For ADRB2 and
ABCG1 the changes were significant; p=0.04 and p,0.001 respectively.
doi:10.1371/journal.pone.0032166.g002
BMS Study
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novel. For ABCG1 this is in line with an earlier in vitro genome
wide expression study that showed that treatment of human
macrophages derived from peripheral blood for seven days with
simvastatin decreased the expression [9].
In total, we report five genes to be differentially expressed in
monocytes, one of which might be fully explained by the use of
statin and aspirin.
ABCA1 is located on 21q22.3 and facilitates cellular cholesterol
and phospholipid efflux to apolipoprotein A1 in macrophages
[15]. Rare loss of function mutations in ABCA1 are associated with
an increased risk of CVD [16]. Decreased expression of this gene,
as we found in our MI patients, might result in decreased
cholesterol efflux, accumulation of lipids in the vessel wall and thus
accelerated atherosclerosis. Decreased expression has also been
reported in subjects at increased risk for CVD, because of FH [17].
We did not have patients with FH in our selection. Previous work
has shown that statins might down regulate ABCA1 expression in
human macrophages [18]. However, further investigation dem-
onstrated that differential expression was reversed to normal in the
presence of cholesterol [9]. This might explain why we did not
observe an effect of statin therapy on ABCA1 expression in the
monocytes.
ABCG1 is located on 9q31.1 and is an ATP binding cassette
reporter that participates in the removal of cholesterol from lipid
laden macrophages to more premature HDL particles [15]. After
statin and aspirin treatment the relative expression of ABCG1
decreased. This implicates that the observed difference between
patients and controls could be due to medication. In line with
these findings, statins have shown to induce decreased macro-
phage expression of ABCG1 [19].
RGS1 is located on 1q31 and is a member of the family of
regulators of G protein signaling (RGS) proteins and mainly
expressed in hematopoietic cells. It may play a major role in the
chemokine-mediated homing of lymphocytes to secondary lym-
phoid organs. Single-nucleotide polymorphisms in this gene have
been associated with spondylarteritis, type 1 diabetes mellitus and
celiac disease [20–22]. In addition they are an independent
prognostic marker of disease survival in melanomas [23]. So far,
there is no clear association with atherogenesis or CVD.
ADRB2 is located on 5q31-q32 and is a cell-surface receptor that
activates adenylylcyclase by coupling to guanine nucleotide
binding proteins (G-proteins).
In vascular smooth muscle cells, the B2 adrenergic receptor
mediates vasodilatation in response to adrenergic agonist. In
healthy myocardium, the receptor mediates chronotropic and
inotropic responses to endogenous and exogenous adrenergic
agents [24]. Common polymorphisms in the ADBR2 (rs1042714;
Gln27Glu and rs1047213; Arg16Gly) allele are associated with a
decreased risk of coronary heart disease incidence in the elderly
and agonist-induced down regulation of ADBR2. The latter is
associated with decreased risk of CVD [24,25]. In line with this,
we observe an increased expression of the ADBR2 gene in the
patients with CVD. After treatment with statin and aspirin the
relative expression of ADRB2 was decreased. This suggests that the
increase, which we initially observed, might have been tempered
by the medication, and may therefore represent a greater
difference between the cases and controls.
FOLR3 is located on 11q13 and is the secreted form of the folate
receptor. It is involved in maintenance of intracellular levels of
folate [26]. In pro atherosclerotic hyperlipidemic animal models,
increased folate receptor expression is associated with activated
macrophages [27]. We found, however, a decreased FOLR3
expression in our MI patients. However, if the folate receptor is
down regulated even in the presence of sufficient circulating folic
acid, cellular levels might be low. This could result in increased
intracellular homocyteine and signaling pathways resulting in
increased atherosclerosis [28].
Our study has several limitations. We hypothesised that in cases
enriched for a genetic background for early onset CVD, genetic
variants might modulate gene expression in circulating monocytes.
However, our expression profiling data, did not reveal shared
common variants, since none of the differentially expressed genes
are in proximity of any of the newly identified loci for CAD [3].
Nevertheless, the observed differential gene expression could be
the result of several other mechanisms, including rare variants and
Figure 3. Differential gene expression in patients versus controls determined qPCR in the replication set. The X-axis depicts the relative
fold changes in gene expression in the patients compared to controls. depicted as the qPCR 2exp DDCT change. Values are given as mean + SD. A
relative fold change of #1o r21 indicates no effect.
doi:10.1371/journal.pone.0032166.g003
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of Zeller et al. [29] who investigated whether gene sequence
variability is linked to phenotypes via gene expression. In a large
cohort of 1490 unrelated healthy individuals, they determined
genome wide expression in monocytes and attempted to associate
this with 10 common risk factors and 675K SNPs. The authors
conclude that the transcriptome of circulating monocytes ap-
peared to be of modest help to dissect the relationship between
genome variability and complex human traits. With the exceptions
of the LPL locus and the 9p21 locus, none of the other
cardiovascular risk loci were found to be associated with genome
wide expression [29].
The number of genes and relative change in gene expressional
profiles between patients and controls were small (,4 fold), which
is probably explained by the selection of patients only in a
clinically stable phase. Because of the small number of genes
differentially expressed; we were not able to identify large
differentially regulated pathways. Although our findings in the
whole genome expression arrays are strengthened by their
validation by qPCR the small fold changes would not make these
genes robust biomarkers for CAD.
In our attempt to correct our results for the effects of medication
we selected medication which was most frequently used by the
cases and based on their mode of action anticipated to modulate
monocyte gene transcription. We have not investigated the effect
of the less frequently used drugs such as ACE-inhibitors and beta-
blockers. Tone et al. studied the effect of angiotensin II type 1
agonist on monocytes in vivo [30]. Nineteen genes were
differentially expressed after 24 hour incubation of macrophages.
However none of these were differentially expressed in our
experiments.
In addition, there were two major differences between our study
and replication group. The age of onset of disease was much
younger in our initial study cohort (36.6 years vs. 43.8). In addition
all cases in the study group suffered from a MI whereas only 54%
in the replication group.
The differentials expression identified by microarray of ABCA1,
RGS1 and ADBR2 was confirmed by qPCR. The results for ABCG1
and FOLR3 were not reproducible by qPCR and therefore require
further validation to confirm or refute their differential expression.
In conclusion, we identified three genes in the expression
profiles of circulating monocytes which might be associated with
early atherogenesis. The fold-changes observed for these genes are
relatively small and should be handled with care. However, we
note that the findings were replicated with two independent
techniques in two independent groups. Further work to confirm
these findings is underway in our laboratory.
Materials and Methods
Ethics statement
The study was approved by the Institutional Review Board
of the Academic Medical Centre (AMC) of the University of
Amsterdam and conducted according to the declaration of
Helsinki.
Study group
Twenty-two Caucasian males who suffered a myocardial
infarction (MI) at a mean age of 36.365.7 years with a positive
family history for CVD, were selected from our Premature
Atherosclerosis (PAS) cohort [31]. Exclusion criteria were a history
of Familial Hypercholesterolemia (FH), substance abuse, cancer,
diabetes, a current infection or any other co-morbidity. All eligible
individuals in this study cohort were approached, starting with the
youngest until 22 participants had provided written informed
consent. All patients were in a stable condition at least one year
after their MI and on statin and aspirin therapy as well as other
medication.
Twenty-two, apparently healthy, Caucasian males without a
positive family history of CVD were also invited to participate as
controls. Controls were matched with the cases for age and current
smoking status. Their mean age was 43.163.3 years. Because the
patients were treated with aspirin and statins, a secondary
investigation was carried out in 12 of the healthy controls. They
were retested after treatment with simvastatin 40 mg for 6 weeks,
and aspirin 100 mg in the last two of the six weeks.
Replication group
Another twenty-four Caucasian males who suffered from
proven CAD at a mean age of 43.864.2 years were selected
from the PAS cohort. All other in- and exclusion criteria were
similar to the study group.
Twenty-four apparently healthy individuals were included
matched for age and current smoking status. Their mean age
was 49,965,1 years.
Study procedure
Participants visited the AMC simultaneously. After informed
consent, medical history was obtained, biometrics were carried out
and blood was collected after fasting for at least nine hours. In
addition an ECG was performed on the controls to exclude a silent
past MI. For the first twelve controls to consent, medication was
provided, and they returned after six weeks of medication for
collection of further fasting blood samples.
Monocyte gene expression
Blood was collected for isolation of cells in CTAD tubes (Becton
Dickinson, Alphen aan de Rijn, the Netherlands) and centrifuged
for 20 minutes at 163 g at 20uC. Subsequently, the buffy coat was
collected and monocytes positively selected with CD14+ Dynal
beads (Invitrogen, Dynal Biotech, Oslo, Norway) according to
manufacturer’s instructions.Trizol (Gibco BRL Life Technologies,
Breda, the Netherlands) was added and samples were stored in
Trizol for a maximum of three months at 280uC. Extracted RNA
was quantified with a nanodrop spectrophotometer (NanoDrop
Technologies, Delaware, USA) prior to further purification using
the RNeasy kit (Qiagen, Valencia, CA, USA). Subsequently,
samples were processed using the Illumina RNA Amplification Kit
(Ambion Inc., Austin, TX, USA) following the manufacturer’s
protocol and hybridized to Illumina HumanWG-6 v2 whole-
genome expression microarrays (Illumina, Inc., San Diego, CA,
USA). In accordance with MIAME (Minimum Information About
a Micro-array Experiment) regulations, all data were deposited
into ArrayExpress database at www.ebi.ac.uk.
For validation of the study qPCR was used. qPCR was also
applied to validate our findings in the replication group. A total of
12 ng of RNA was used for reverse transcription, and amplified
using Taqman Transcription Reagents (Applied Biosystems,
Foster City, CA, USA). A no template negative control was
included and all tests were run in duplicate. For validation
the relative expression was compared to the reference
gene Glycerinaldehyd-3-phosphat-Dehydrogenase (GAPDH;
Hs999999o5_m1). All qPCR probes were ordered from Applied
Biosystems by Life Technology, ABI, Amersham, UK. The 96-
well plates were read on the Mx4000 Multiplex Quantitative PCR
System (Stratagene Inc, La Jolla, California, USA) and data
analysed using supplied software. For analysis duplicate wells were
BMS Study
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threshold algorithm enhancements were applied.
Statistical analysis
Statistical analysis of demographics and laboratory values were
performed in SPSS (version 15.0, Chicago, Illinois, USA).
Comparisons were performed with an unpaired t-test; percentages
between two groups were compared by means of x2 tests.
Variables with a skewed distribution were log-transformed prior to
analysis or compared using nonparametric tests. Statistical analysis
of the microarray data was performed in R-statistical package and
Bioconductor (http://www.r-project.org). Raw data was quantile
normalised and filtered to include only features with detection
scores above background.
A fold change cut of 1.5 was used. Paired analysis using
Student’s t-test was carried out across the pairings to identify
differentially expressed genes. Statistical analysis of the qPCR data
was performed in Graphpad Prism version 5. Relative fold
changes due to medication were assessed by performing a Student
t-test pre and post medication on the delta delta CTs. Differences
between microarray intensities and relative expression as deter-
mined by qPCR were also tested by performing a unpaired
Student t-test. For all experiments a p-value,0.05 was considered
statistically significant.
Supporting Information
Table S1 Baseline characteristics Patients and Controls
in the Replication study. Data are presented as mean 6
standard deviation (sd) or median (interquartile range)*. Hx
indicates history; LDL indicates low-density lipoprotein and HDL
indicates high-density lipoprotein. All Lipid values are un-
medicated. At time of inclusion all patients received statin therapy.
(DOC)
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